The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth - inhibitory effects on CD34+/CD38+ and CD34+/CD38- AML progenitor cells

Current Cancer Drug Targets

Volumn 12, Issue 1, 2012, Pages 51-63

  Herrmann, H ^a   Kneidinger, M ^a   Cerny Reiterer, S ^a   Rulicke T ^b   Willmann, M ^b   Gleixner, K V ^a   Blatt, K ^a   Hormann G ^c   Peter, B ^a,b   Samorapoompichit, P ^c   Pickl, W ^d   Bharate, G Y ^e   Mayerhofer, M ^c   Sperr, W R ^a   Maeda, H ^e   Valent, P ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e SOJO UNIVERSITY   (Japan)

Author keywords

AML; HO 1; Hsp32; Survival; Targeting

Indexed keywords

CASPASE 3; CD34 ANTIGEN; CD38 ANTIGEN; HEAT SHOCK PROTEIN 32; MESSENGER RNA; PEGYLATED ZINC PROTOPORPHYRIN; PROTEIN INHIBITOR; STYRENE MALEIC ACID COPOLYMER MICELLE ENCAPSULATED ZINC PROTOPORPHYRIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CD34 SELECTION; CELL PROLIFERATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; NICK END LABELING; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; WESTERN BLOTTING;

AGED; ANIMALS; ANTIGENS, CD34; ANTIGENS, CD38; FEMALE; GROWTH INHIBITORS; HEME OXYGENASE-1; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MALEATES; MEMBRANE GLYCOPROTEINS; METALLOPORPHYRINS; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASTIC STEM CELLS; POLYETHYLENE GLYCOLS; POLYSTYRENES; STEM CELLS; TUMOR CELLS, CULTURED; U937 CELLS;

EID: 84855822788     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912798888992     Document Type: Article

References (43)

1. Estey, E.; Döhner, H. Acute myeloid leukaemia. Lancet 2006, 368, 1894-1907.
2. Vardiman, J. W.; Thiele, J.; Arber, D. A.; Brunning, R. D.; Borowitz, M. J.; Porwit, A.; Harris, N. L.; Le Beau, M. M.; Hellstrom-Lindberg, E.; Tefferi, A.; Bloomfield, C. D. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114, 937-951.
3. Haferlach, T. Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 2008, 400-411.
4. Kornblau, S. M.; Tibes, R.; Qiu, Y.; Chen, W.; Kantarjian, H. M.; Andreeff, M.; Coombes, K. R.; Mills, G. B. Functional proteomic profiling of AML predicts response and survival. Blood 2009, 113, 154-164.
5. Sperr, W. R.; Piribauer, M.; Wimazal, F.; Fonatsch, C.; Thalhammer-Scherrer, R.; Schwarzinger, I.; Geissler, K.; Knöbl, P.; Jäger, U.; Lechner, K.; Valent, P. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Clin. Cancer Res. 2004, 10, 3965-3971.
6. Neubauer, A.; Maharry, K.; Mrózek, K.; Thiede, C.; Marcucci, G.; Paschka, P.; Mayer, R. J.; Larson, R. A.; Liu, E. T.; Bloomfield, C. D. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J. Clin. Oncol. 2008, 26, 4603-4609.
7. Schmid, C.; Kolb, H. J. Allogeneic stem cell transplantation in the management of acute myeloid leukemia. Med. Klin. 2007, 102, 317-23.
8. Craddock, C.; Labopin, M.; Pillai, S.; Finke, J.; Bunjes, D.; Greinix, H.; Ehninger, G.; Steckel, N. K.; Zander, A. R.; Schwerdtfeger, R.; Buchholz, S.; Kolb, H. J.; Volin, L.; Fauser, A.; Polge, E.; Schmid, C.; Mohty, M.; Rocha, V. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011, 25, 808-813.
9. Ravandi, F.; Talpaz, M.; Kantarjian, H.; Estrov, Z. Cellular signalling pathways: new targets in leukaemia therapy. Br. J. Haematol. 2002, 116, 57-77.
10. Stirewalt, D. L.; Meshinchi, S.; Radich, J. P. Molecular targets in acute myelogenous leukemia. Blood Rev. 2003, 17, 15-23.
11. Deininger, M. W.; Druker, B. J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. 2003, 55, 401-423.
12. Leitner, A. A.; Hochhaus, A.; Müller, M. C. Current treatment concepts of CML. Curr. Cancer Drug Targets 2011, 11, 31-43.
13. Stone, R. M. Novel therapeutic agents in acute myeloid leukemia. Exp. Hematol. 2007, 35(S1), 163-166.
14. Chant, I. D.; Rose, P. E.; Morris, A. G. Susceptibility of AML cells to In vitro apoptosis correlates with heat shock protein 70 (hsp 70) expression. Br. J. Haematol. 1996, 93, 898-902.
15. Larocca, L. M.; Ranelletti, F. O.; Maggiano, N.; Rutella, S.; La Barbera, E. O.; Rumi, C.; Serra, F.; Voso, M. T.; Piantelli, M.; Teofili, L.; Leone, G. Differential sensitivity of leukemic and normal hematopoietic progenitors to the killing effect of hyperthermia and quercetin used in combination: role of heat-shock protein-70. Int. J. Cancer 1997, 73, 75-83.
16. Thomas, X.; Campos, L.; Mounier, C.; Cornillon, J.; Flandrin, P.; Le, Q. H.; Piselli, S.; Guyotat, D. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk. Res. 2005, 29, 1049-1058.
17. Brouard, S.; Otterbein, L. E.; Anrather, J.; Tobiasch, E.; Bach, F. H.; Choi, A. M.; Soares, M. P. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J. Exp. Med. 2000, 192, 1015-1026.
18. Alcaraz, M. J.; Fernandez, P.; Guillen, M. I. Anti-inflammatory actions of the heme oxygenase-1 pathway. Curr. Pharm. Des. 2003, 9, 2541-2551.
19. Goodman, A. I.; Choudhury, M.; da Silva, J. L.; Schwartzman, M. L.; Abraham, N. G. Overexpression of the heme oxygenase gene in renal cell carcinoma. Proc. Soc. Exp. Biol. Med. 1997, 214, 54-61.
20. Doi, K.; Akaike, T.; Fujii, S; Tanaka, S.; Ikebe, N.; Beppu, T.; Shibahara, S.; Ogawa, M.; Maeda, H. Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br. J. Cancer 1999, 80, 1945-1954.
21. Tanaka, S.; Akaike, T.; Fang, J.; Beppu, T.; Ogawa, M.; Tamura, F.; Miyamoto, Y.; Maeda, H. Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. Br. J. Cancer 2003, 88, 902-909.
22. Fang, J.; Sawa, T.; Akaike, T.; Akuta, T.; Sahoo, S. K.; Khaled, G.; Hamada, A.; Maeda, H. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 2003, 63, 3567-3574.
23. Fang, J.; Sawa, T.; Akaike, T.; Greish, K.; Maeda, H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int. J. Cancer 2004, 109, 1-8.
24. Nakamura, H.; Fang, J.; Gahininath, B.; Tsukigawa, K.; Maeda, H. Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; unique intracellular disintegration of SMA micelles. J. Control Release 2011, 155, 367-375.
25. Mayerhofer, M.; Florian, S.; Krauth, M. T.; Aichberger, K. J.; Bilban, M.; Marculescu, R.; Printz, D.; Fritsch, G.; Wagner, O.; Selzer, E.; Sperr, W. R.; Valent, P.; Sillaber, C. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer. Res. 2004, 64, 3148-3154.
26. Mayerhofer, M.; Gleixner, K. V.; Mayerhofer, J.; Hoermann, G.; Jaeger, E.; Aichberger, K. J.; Ott, R. G.; Greish, K.; Nakamura, H.; Derdak, S.; Samorapoompichit, P.; Pickl, W. F.; Sexl, V.; Esterbauer, H.; Schwarzinger, I.; Sillaber, C.; Maeda, H.; Valent, P. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 2008, 111, 2200-2210.
27. Iyer, A. K.; Greish, K.; Seki, T.; Okazaki, S.; Fang, J.; Takeshita, K.; Maeda, H. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J. Drug Target. 2007, 15, 496-506.
28. Bennett, J. M.; Catovsky, D.; Daniel, M. T.; Flandrin, G.; Galton, D. A.; Gralnick, H. R.; Sultan, C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br. J. Haematol. 1976, 33, 451-458.
29. Bennett, J. M.; Catovsky, D.; Daniel, M. T.; Flandrin, G.; Galton, D. A.; Gralnick, H. R.; Sultan, C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Intern. Med. 1985, 103, 620-625.
30. Florian, S.; Sonneck, K.; Hauswirth, A. W.; Krauth, M. T.; Schernthaner, G. H.; Sperr, W. R.; Valent, P. Detection of molecular targets on the surface of CD34+/CD38--stem cells in various myeloid malignancies. Leuk. Lymphoma 2006, 47, 207-222.
31. Hauswirth, A. W.; Florian, S.; Printz, D.; Sotlar, K.; Krauth, M. T.; Fritsch, G.; Schernthaner, G. H.; Wacheck V.; Selzer, E.; Sperr, W. R.; Valent, P. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur. J. Clin. Invest. 2007, 37, 73-82.
32. Mayerhofer, M.; Gleixner, K. V.; Hoelbl, A.; Florian, S.; Hoermann, G.; Aichberger, K. J.; Bilban, M.; Esterbauer, H.; Krauth, M. T.; Sperr, W. R.; Longley, J. B.; Kralovics, R.; Moriggl, R.; Zappulla, J.; Liblau, R. S.; Schwarzinger, I.; Sexl, V.; Sillaber, C.; Valent, P. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J. Immunol. 2008, 180, 5466-5476.
33. Tauber, S.; Jais, A.; Jeitler, M.; Haider, S.; Husa, J.; Lindroos, J.; Knöfler, M; Mayerhofer, M.; Pehamberger, H.; Wagner, O.; Bilban, M. Transcriptome analysis of human cancer reveals a functional role of heme oxygenase-1 in tumor cell adhesion. Mol. Cancer 2010, 9, 200.
34. Van Cruchten, S.; Van Den Broeck, W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat. Histol. Embryol. 2002, 31, 214-223.
35. Samorapoompichit, P.; Kiener, H. P.; Schernthaner, G. H.; Jordan, J. H.; Agis, H.; Wimazal, F.; Baghestanian, M.; Rezaie-Majd, A.; Sperr, W. R.; Lechner, K.; Valent, P. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001, 98, 2580-2583.
36. Gleixner, K. V.; Mayerhofer, M.; Vales, A.; Gruze, A.; Hoermann, G.; Cerny-Reiterer, S.; Lackner, E.; Hadzijusufovic, E.; Herrmann, H.; Iyer, A. K.; Krauth, M. T.; Pickl, W. F.; Marian, B.; Panzer-Grümayer, R.; Sillaber, C.; Maeda, H.; Zielinski, C.; Valent, P. Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy. Curr. Cancer Drug Targets 2009, 9, 675-689.
37. La, P.; Fernando, A. P.; Wang, Z.; Salahudeen, A.; Yang, G.; Lin, Q.; Wright, C. J.; Dennery, P. A. Zinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition. J. Biol. Chem. 2009, 284, 36302-36311.
38. Bonnet, D.; Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737.
39. Hope, K. J.; Jin, L.; Dicko, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in selfrenewal capacity, Nat. Immunol. 2001, 5, 738-743.
40. Valent, P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr. Cancer Drug Targets. 2011, 11, 56-71.
41. Taussig, D. C.; Miraki-Moud, F.; Anjos-Afonso, F.; Pearce, D. J.; Allen, K.; Ridler, C.; Lillington, D.; Oakervee, H.; Cavenagh, J.; Agrawal, S. G.; Lister, T. A.; Gribben, J. G.; Bonnet, D. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008, 112, 568-575.
42. Rushworth, S. A.; Macewan, D. J. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 2008, 111, 3793-3801.
43. Rushworth, S. A.; Bowles, K. M.; Raninga, P.; MacEwan, D. J. NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction. Cancer Res. 2010, 70, 2973-2983.